5), treated with antiviral therapy for hepatitis B
or C, prior lipid-lowering medications for ≥8 weeks,
or with other significant comorbid conditions (eg, cancer, significant cardiovascular, uncontrolled diabetes mellitus) were excluded.
All pre-enrollment liver enzymes levels were similar for both treatment groups. The mean historical ALT and AST values were statistically significantly lower in the pravastatin group than in the placebo group (P = .